Literature DB >> 18977247

NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model of tauopathy.

Miroslava Korenova1, Norbert Zilka, Zuzana Stozicka, Ondrej Bugos, Ivo Vanicky, Michal Novak.   

Abstract

We have previously shown that transgenic rats expressing misfolded tau protein developed neurofibrillary tangles and axonal degeneration in the brain and spinal cord, which led to impairment of sensorimotor and neuromuscular functions. To quantify neurobehavioral phenotype of the transgenic rats we have designed a testing protocol and a novel scoring system - NeuroScale - that reliably reflects progression of functional impairment of transgenic rats. NeuroScale consists of three variants of beam walking test with different sensitivity and a rapid neuromuscular and neurological examination, where animal performance is evaluated and scored according to a pre-defined rating scale. The range of the rating scale was developed to increase homogeneity of the collected behavioral data without lowering sensitivity of the testing methods. Finally, all awarded points were summed up to obtain a complete quantitative behavioral readout, the NeuroScale score, from animals under investigation. Increase in the NeuroScale score faithfully mirrored disease progression and allowed statistically significant discrimination (p<0.001) between behavioral responses of transgenic and control animals during the whole disease process. The method was suitable for a high-throughput test whereby an experienced operator can examine up to 60 rats per day. We show that this multi-test battery with novel sensitive scoring system - NeuroScale - represents a rapid, simple to perform, high throughput method for quantitative evaluation of behavioral phenotype of transgenic rats that could serve as a valuable primary read-out for in vivo validation of therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977247     DOI: 10.1016/j.jneumeth.2008.09.027

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  10 in total

1.  CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.

Authors:  Norbert Zilka; Miroslava Korenova; Branislav Kovacech; Khalid Iqbal; Michal Novak
Journal:  Acta Neuropathol       Date:  2010-04-09       Impact factor: 17.088

2.  Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO.

Authors:  Tomoko Kurata; Violeta Lukic; Miki Kozuki; Daisuke Wada; Kazunori Miyazaki; Nobutoshi Morimoto; Yasuyuki Ohta; Kentaro Deguchi; Toru Yamashita; Nozomi Hishikawa; Kosuke Matsuzono; Yoshio Ikeda; Tatsushi Kamiya; Koji Abe
Journal:  Transl Stroke Res       Date:  2014-01-17       Impact factor: 6.829

Review 3.  Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies.

Authors:  Miroslava Korenova; Zuzana Stozicka
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

4.  Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.

Authors:  Gustavo Basurto-Islas; Julie Blanchard; Yunn Chyn Tung; Jose R Fernandez; Michael Voronkov; Maxwell Stock; Sherry Zhang; Jeffry B Stock; Khalid Iqbal
Journal:  Neurobiol Aging       Date:  2014-06-17       Impact factor: 4.673

Review 5.  Beyond the rat models of human neurodegenerative disorders.

Authors:  Ondrej Bugos; Mangesh Bhide; Norbert Zilka
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

6.  Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.

Authors:  Zuzana Stozicka; Norbert Zilka; Petr Novak; Branislav Kovacech; Ondrej Bugos; Michal Novak
Journal:  J Neuroinflammation       Date:  2010-10-12       Impact factor: 8.322

7.  First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.

Authors:  Eva Kontsekova; Norbert Zilka; Branislav Kovacech; Petr Novak; Michal Novak
Journal:  Alzheimers Res Ther       Date:  2014-08-01       Impact factor: 6.982

8.  Meloxicam blocks neuroinflammation, but not depressive-like behaviors, in HIV-1 transgenic female rats.

Authors:  Christina L Nemeth; Erica R Glasper; Constance S Harrell; Sanjana A Malviya; Jeffrey S Otis; Gretchen N Neigh
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

9.  Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment.

Authors:  Xiaochuan Wang; Julie Blanchard; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

Review 10.  Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead.

Authors:  Petr Novak; Eva Kontsekova; Norbert Zilka; Michal Novak
Journal:  Front Neurosci       Date:  2018-11-02       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.